Formed in 2012, the company focuses on technologies for patients suffering from sacroiliac (SI) joint and broader sacro-pelvic disorders. Tenon is positioned as a specialized orthopedic device company pursuing regulatory clearances and commercial adoption in the SI joint fusion market, though it remains in early commercialization with limited scale.
Cyborg Score Rationale
Tenon faces significant headwinds: the company is unprofitable, trades well below its IPO price, has minimal market capitalization (~$5-7M), and demonstrates falling stock momentum. Capital constraints have required multiple funding rounds including preferred stock issuances and convertible debt placements. However, the company addresses a legitimate clinical need in a niche but growing orthopedic market.
Top Insights
Tenon Medical, Inc. identified via verified ticker (TNON:NASDAQ).
Preliminary analysis underway — comprehensive insights appear when deep research completes.
Industry classification and competitive landscape being analyzed.
Named Competitors
SI Joint Fusion Systems — Broad orthopedic device company with SI fusion offerings
SI Joint Fusion — Large-cap orthopedic device manufacturer with SI joint solutions
Spinal Fusion Systems — Large multinational medical device company with spinal fusion portfolio
Recent Developments
(March 2026) Raised $4.3M in private placement of senior convertible promissory notes
(Q4 2025) Reported robust revenue growth driven by increased adoption of Catamaran SI Joint Fusion System
(2024) Received US Patent and Trademark Office notices of allowance for technology
Open the full interactive Tenon Medical, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.